339 related articles for article (PubMed ID: 31484367)
1. Early Stage Glycosylation Biomarkers in Alzheimer's Disease.
Regan P; McClean PL; Smyth T; Doherty M
Medicines (Basel); 2019 Sep; 6(3):. PubMed ID: 31484367
[TBL] [Abstract][Full Text] [Related]
2. Human Brain and Blood N-Glycome Profiling in Alzheimer's Disease and Alzheimer's Disease-Related Dementias.
Yu L; Huo Z; Yang J; Palma-Gudiel H; Boyle PA; Schneider JA; Bennett DA; Zhao J
Front Aging Neurosci; 2021; 13():765259. PubMed ID: 34776937
[TBL] [Abstract][Full Text] [Related]
3. N-glycan and Alzheimer's disease.
Kizuka Y; Kitazume S; Taniguchi N
Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2447-2454. PubMed ID: 28465241
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
5. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
6. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
[TBL] [Abstract][Full Text] [Related]
7. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
[TBL] [Abstract][Full Text] [Related]
8. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.
Volloch V; Olsen B; Rits S
Ann Integr Mol Med; 2020; 2(1):90-114. PubMed ID: 32617536
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
11. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
13. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein.
Hampel H; Goernitz A; Buerger K
Brain Res Bull; 2003 Aug; 61(3):243-53. PubMed ID: 12909294
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
15. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
[TBL] [Abstract][Full Text] [Related]
16. Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer's disease brain, serum and cerebrospinal fluid towards potential biomarker discovery.
Gizaw ST; Ohashi T; Tanaka M; Hinou H; Nishimura S
Biochim Biophys Acta; 2016 Aug; 1860(8):1716-27. PubMed ID: 26968461
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
[TBL] [Abstract][Full Text] [Related]
18. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
[TBL] [Abstract][Full Text] [Related]
19. Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease.
Ryan P; Patel B; Makwana V; Jadhav HR; Kiefel M; Davey A; Reekie TA; Rudrawar S; Kassiou M
ACS Chem Neurosci; 2018 Jul; 9(7):1530-1551. PubMed ID: 29782794
[TBL] [Abstract][Full Text] [Related]
20. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
Cavedo E; Lista S; Khachaturian Z; Aisen P; Amouyel P; Herholz K; Jack CR; Sperling R; Cummings J; Blennow K; O'Bryant S; Frisoni GB; Khachaturian A; Kivipelto M; Klunk W; Broich K; Andrieu S; de Schotten MT; Mangin JF; Lammertsma AA; Johnson K; Teipel S; Drzezga A; Bokde A; Colliot O; Bakardjian H; Zetterberg H; Dubois B; Vellas B; Schneider LS; Hampel H
J Prev Alzheimers Dis; 2014 Dec; 1(3):181-202. PubMed ID: 26478889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
